The Alliance for Safe Biologic Medicines (ASBM) submitted comments to the FDA outlining recommended steps to ensure that patient safety is at the forefront of the biosimilars pathway. Read the ASBM Comments.
Media Room
ASBM Submits Comments to FDA
Thursday, April 19th, 2012